ArticleAAPS PharmSciTech2025
Fast-Dissolving Pullulan Film as a Solid Dosage Form for Sublingual Administration of Nifedipine-Loaded Nanocapsules.
Article in AAPS PharmSciTech, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Development of Antimicrobial Chitosan-Silver and Chitosan-Gold Nanocomposite Films by 3D Printing for Skin Application.ACS omega · 2026Article
- Nanocomposite sublingual films: a scoping review of formulation trends and translational gaps.Drug delivery and translational research · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Fast-dissolving pullulan films were developed as a final dosage form for the sublingual administration of nanocapsules containing nifedipine (NIFE). Eudragit® RS100 nanocapsule suspensions presenting 1 mg/mL of NIFE, 150 nm in size, and positive zeta potential were converted into films using pullulan through the solvent-casting method. The films retained the nanometric size profile of the original suspension and NIFE homogeneity content. The conversion of the nanocapsule suspension into films improved the stability of NIFE. SEM analysis identified smooth, uniform surfaces, while AFM revealed increased surface roughness in films containing nanocapsules. All films exhibited high deformability and flexibility, ensuring comfortable sublingual administration. The contact angle of the films was less than 90º, indicating a hydrophilic surface, corroborating the high swelling index (> 200%). Moreover, the films disintegrated and dispersed quickly, with values less than 3 min and 30 s, respectively, confirming their fast-dissolving nature. The in vitro release showed NIFE maintained its controlled release, reaching 66.95 ± 4.18% in 24 h. The porcine mucosa study demonstrated NIFE's ability to permeate sublingual tissue in 3.12 ± 0.89%.cm
Indexed as
Identifiers
40731208What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.